NCT00824590View on ClinicalTrials.gov

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Alzheimer's DiseaseHuntington's Disease
Interventions
DRUG

Dimebon

a single oral dose of 20 mg Dimebon

DRUG

Dimebon

a single oral dose of 20 mg Dimebon

Trial Locations (2)

33169

Pfizer Investigational Site, Miami

55114

Pfizer Investigational Site, Saint Paul

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT00824590 - A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function | Biotech Hunter | Biotech Hunter